A detailed history of Royal Bank Of Canada transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 30,260 shares of XERS stock, worth $102,884. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,260
Previous 27,347 10.65%
Holding current value
$102,884
Previous $61,000 40.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.06 - $2.96 $6,000 - $8,622
2,913 Added 10.65%
30,260 $86,000
Q2 2024

Aug 14, 2024

BUY
$1.7 - $2.45 $14,982 - $21,591
8,813 Added 47.55%
27,347 $61,000
Q1 2024

Nov 05, 2024

SELL
$2.04 - $3.22 $17,978 - $28,377
-8,813 Reduced 32.23%
18,534 $40,000
Q1 2024

May 15, 2024

SELL
$2.04 - $3.22 $75,010 - $118,399
-36,770 Reduced 66.49%
18,534 $40,000
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $47,785 - $76,716
32,507 Added 142.59%
55,304 $129,000
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $14,427 - $21,560
8,015 Added 54.22%
22,797 $42,000
Q2 2023

Aug 14, 2023

BUY
$1.82 - $2.98 $7,926 - $12,977
4,355 Added 41.77%
14,782 $38,000
Q1 2023

May 15, 2023

SELL
$1.03 - $1.63 $8,064 - $12,762
-7,830 Reduced 42.89%
10,427 $16,000
Q4 2022

Feb 14, 2023

BUY
$1.14 - $1.65 $14,871 - $21,524
13,045 Added 250.29%
18,257 $24,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $12,512 - $17,626
-9,133 Reduced 63.67%
5,212 $9,000
Q2 2022

Aug 15, 2022

SELL
$1.48 - $2.64 $43,008 - $76,718
-29,060 Reduced 66.95%
14,345 $22,000
Q1 2022

May 16, 2022

BUY
$2.0 - $2.87 $46,610 - $66,885
23,305 Added 115.95%
43,405 $111,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $36,180 - $58,893
20,100 New
20,100 $59,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $462M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.